NEW YORK — Nanomix said on Thursday that it has signed an agreement under which Biotron will distribute its eLab point-of-care immunoassay and chemistry diagnostic system and related sepsis panel in Israel.
Nanomix's eLab system comprises a handheld analyzer and disposable test cartridge. Under the terms of the deal, Tel Aviv-based Biotron will distribute the system, along with the CE-marked Nanomix S1 Panel cartridge — which measures the critical infection biomarkers procalcitonin, C-reactive protein, and lactate in venous whole blood or plasma — in Israel. Biotron will also distribute future test cartridges in Israel as they become available.
Additional terms of the agreement were not disclosed.
"Improving sepsis patient outcomes is a global initiative, and the Nanomix eLab system provides timely, mobile, and accurate diagnostic results to support the critical need of earlier patient diagnosis," Nanomix Chief Commercial Officer John Hardesky said in a statement.
Earlier this year, Emeryville, California-based Nanomix received CE marking for its eLab COVID-19 antigen test.